CorMedix (NYSEAMERICAN:CRMD) is scheduled to post its quarterly earnings results before the market opens on Thursday, March 15th. Analysts expect CorMedix to post earnings of ($0.13) per share for the quarter.
Shares of CorMedix (NYSEAMERICAN:CRMD) opened at $0.29 on Wednesday. CorMedix has a 1 year low of $0.27 and a 1 year high of $2.14. The company has a market cap of $23.37, a P/E ratio of -0.48 and a beta of 0.60.
A hedge fund recently raised its stake in CorMedix stock. Vanguard Group Inc. boosted its position in shares of CorMedix Inc. (NYSEAMERICAN:CRMD) by 3.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,208,894 shares of the biotechnology company’s stock after purchasing an additional 35,148 shares during the quarter. Vanguard Group Inc. owned 2.98% of CorMedix worth $518,000 as of its most recent SEC filing.
CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.